Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The reality: Injectables Still set the efficacy ceiling Strongest outcomes + label support Oral drugs Lower efficacy (~1113%) But expand the market significantly Key insight: This is not one oral category Oral semaglutide requires fasting + waiting Orforglipron taken anytime The winner may be the least inconvenient drug, not the most effective The Hidden Problem: Persistence This is the part almost no one talks about: Only ~24.5% of patients remain on therapy at 12 months ~20% switch therapies within a year After stopping: Weight regain 0.8 kg per month Let that sink in
Transition plan to insulin / discontinuing GLP-1 RA
Peak Wellness is best for cost-conscious patients willing to try a newer platform in exchange for potentially significant savings on compounded semaglutide or tirzepatide
Furthermore, the findings related to colorectal cancer incidence illustrate the issue of rare outcomes among clinical trials, owing to the low incidence rates of colorectal cancer over shorter follow-up periods [45]
Confe en su equipo de Nurx para recibir apoyo con el seguimiento del progreso, contenido educativo sobre dieta saludable y ejercicio, y ajustes adecuados del tratamiento
University of California, Davis, Department of Nutrition
